Compare SNGX & SLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | SLE |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.0M |
| IPO Year | 2006 | 2019 |
| Metric | SNGX | SLE |
|---|---|---|
| Price | $0.37 | $3.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 608.4K | 20.3K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $119,371.00 | ★ $2,064,000.00 |
| Revenue This Year | N/A | $24.86 |
| Revenue Next Year | N/A | $49.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 90.41 |
| 52 Week Low | $0.28 | $0.48 |
| 52 Week High | $6.23 | $11.43 |
| Indicator | SNGX | SLE |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 39.31 |
| Support Level | $0.28 | $0.51 |
| Resistance Level | $0.41 | $3.43 |
| Average True Range (ATR) | 0.02 | 0.18 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 15.68 | 24.00 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.